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In recent years, the array of options used in screening for cervical cancer has been expanded substantially by the development of new technologies such as liquidbased cytology (LBC) and by testing for human papillomavirus (HPV). Also, empirical data about the natural history of HPV and the effect of various strategies for screening and triage of abnormal cytology results have allowed for robust scrutiny of evidence-based screening algorithms. These changes have resulted in several organizations substantially revising their prior screening guidelines for cervical cancer.
Epidemiology Of Cervical Cancer
Cervical cancer mortality has decreased substantially by the detection of precursor lesions and earlier-stage cancers by means of Papanicolaou testing. However, invasive cervical cancer remains the cause of death for almost 4000 women each year in the United States, with most cases occurring in unscreened (and suboptimally screened) women. Virtually all cases of squamous cell cervical cancer arise in the context of prior infection with a high-risk type of HPV (ie, one known to increase the chance of cervical neoplasia). Cervical HPV infection is acquired sexually. The peak incidence and prevalence of HPV infection occur in women younger than 25 years, but most infections (70%-80%) in younger women are transient and do not progress to cervical neoplasia.
When infection and cervical abnormalities progress, the vast majority do so in an orderly fashion from less severe to more severe lesions before transitioning to an invasive cancer. Glandular lesions may be an important exception to this rule. Reliable early detection of cervical adenocarcinoma or the precursor lesion, adenocarcinoma in situ (AIS), remains a challenge. Because glandular lesions follow a less predictable clinical course and because the sensitivity for detecting glandular lesions is believed to be decreased compared with squamous lesions, all interpretations of Papanicolaou test results suggesting a glandular cell abnormality require meticulous and cautious follow-up.
Behavioral risk factors for squamous cell cervical cancer include earlier age at onset of sexual intercourse and larger number of lifetime partners. Cigarette smoking is the most important nonsexual risk behavior, independently increasing the risk 2-to 4-fold in several studies.
Initiation And Frequency Of Screening
Screening is defined as testing of a healthy individual.
It is important to remember that the following discussion should not be generalized to the evaluation of a patient with signs or symptoms of cervical disease or to the follow-up of a woman with prior abnormal results from Papanicolaou testing. Screening recommendations attempt to balance the potential for good (prevention of cancer) against the potential for harm, in this case needless worry, expense, or intervention.
Both the American Cancer Society (ACS) and the US Preventive Services Task Force (USPSTF) recommend that all women begin annual Papanicolaou testing approximately 3 years after onset of sexual activity or at age 21 years (whichever occurs first). Although screening women who have never been sexually active has little value, this recommendation is based on the generally high prevalence of sexual activity by that age and on concerns that clinicians may not always obtain accurate sexual histories.
Women with atypical squamous cells of undetermined significance (ASCUS) or a low-grade squamous intraepithelial lesion (LSIL) whose initial evaluation reveals no dysplasia should be screened again at 6 and 12 months for LSIL or at 12 months for ASCUS, followed by screening every year (or every 2 years if using LBC and following ACS guidelines) until 5 years from the last abnormal result. Women with a history of higher-grade lesions are considered under "surveillance" rather than being "screened" and should be monitored at shorter intervals under the guidance of a gynecologist. 
Liquid-Based Cytology
Options for Papanicolaou testing now include conventional (slide smear) or LBC analysis. Recommendations increasingly favor the LBC methods for reasons discussed subsequently.
With LBC, the sample is suspended in a liquid that is centrifuged, and then cells are recovered from the centrifuged sediment. This technique provides a cleaner, more accurate preparation for microscopic analysis than conventional Papanicolaou testing for various reasons (including improved transfer of cellular material, more uniform distribution on the slide, a decrease in obscuring background factors, and less air-drying artifact). In most studies, LBC preparation has a slightly higher sensitivity than does preparation based on the conventional method, with approximately equivalent specificity. The LBC preparation also has been found to result in a higher rate of "satisfactory" test results. The ACS considered the higher sensitivity (more frequent detection of actual disease), increased cost, and chance of increased harm (patient anxiety and possible treatment of clinically insignificant lesions) with LBC Papanicolaou tests when formulating their recommendation to increase the screening interval for LBC methods to every 2 years.
Another advantage of LBC is the ability to perform HPV testing on the same sample when indicated (eg, for ASCUS).
It is important to note that optimal specimen collection for LBC Papanicolaou testing requires use of a plastic rather than a wooden spatula. The endocervix is sampled with the usual brush instrument or with a plastic spatula that incorporates an endocervical "broom." The collection device(s) must be swirled in the collection medium for the recommended 30 seconds and then discarded or the ends of the collection devices are cut or broken off and submitted in the collection medium, depending on manufacturer's directions. Physicians should review instructions for the particular test used in their own clinical settings. 
HPV DNA Testing

Treatment Of Patients With Abnormal Results From Papanicolaou Testing
To more effectively communicate results to clinicians, the National Cancer Institute issued a revision in 2001 of the "Bethesda System" terminology used to report cervical cytology. The major types of intraepithelial lesions in that classification are listed in Table 1 . A consensus conference also was convened that year to develop evidence-based guidelines for treating women with abnormal results from Papanicolaou testing. These guidelines form the basis of the following discussion, and the consensus conference recommendations are summarized in Table 2 . The ability to test for high-risk HPV types offers a third and arguably the best option for treating patients with ASCUS results. With this protocol, women who test positive for high-risk HPV types are referred for colposcopy, whereas those testing negative are advised to undergo screening again in 1 year. This method of triage for results that indicate ASCUS is highly sensitive, with a well-documented negative predictive value of 98% or more. This method is preferable when it can be performed as a reflex test (initially LBC is used so that HPV testing is performed without an additional patient visit when ASCUS results are present). A recent analysis showed that reflex HPV testing is more cost-effective than alternative strategies for follow-up of ASCUS results.
Specimen Adequacy
In the setting of reflex HPV testing for ASCUS cytology, should a woman infected with a high-risk HPV type ever be tested for HPV again? In young women (in whom HPV infection usually remits spontaneously), repeated HPV testing with subsequent Papanicolaou testing may continue to be useful for interpreting ASCUS results. Repeated HPV testing in older women (in whom the HPV infection is more likely to be chronic) is probably of less value, but a discriminating age cutoff has not been identified. Postmenopausal women with clinical or cytologic evidence of atrophy who have ASCUS are at lower risk of clinically important neoplasia than are premenopausal women. Although use of reflex testing for HPV generally is preferred in this population as well, a reasonable alternative suggested by some guidelines is to treat with vaginal estrogen for 4 to 6 months and then repeat Papanicolaou testing 1 week after therapy is completed. The Papanicolaou test should be repeated again in 4 to 6 months. If results from both follow-up tests are normal, then routine screening can be resumed. If results are abnormal from either follow-up test, the patient should be referred for colposcopy.
Another exception includes women who are immunosuppressed due to HIV, lymphoproliferative disorder, corticosteroid use, or posttransplantation immunosuppression. All immunosuppressed women with ASCUS results should be referred for colposcopy.
In HIV-positive patients, colposcopy should be performed regardless of CD4 count, HIV viral load, or use or nonuse of antiretroviral therapy.
Other Abnormalities On Papanicolaou Testing
Patients with abnormalities other than ASCUS on Papanicolaou testing should be referred for specialty care. The following brief summary is a supplement to specialty consultation for primary care physicians. The maximum screening interval should be 3 years, with more frequent screening at onset and in high-risk situations (HIV, prior dysplasia, chronic immunosuppression).
Although more expensive, LBC has the advantages of improved sensitivity for LSIL and higher-grade lesions as well as fewer "unsatisfactory" and "obscured by blood/inflammation" readings and provides the ability to perform HPV testing on the same specimen (when indicated). 
